Figure 2

Selected TKIs inhibit cytokine responses in adipocytes induced by bacterial cell wall-mediated components, but not endotoxin. Levels of Cxcl1 released from 3T3-L1 adipocytes after stimulation with the Nod1 ligand FK565 (10 μg/mL) for 48 h and pre-incubated for 1 h with 1 or 5 μM of the TKIs gefitinib, SB203580 or imatinib (A) n = 6. Time course of FK565-stimulated Cxcl1 secretion in 3T3-L1 adipocytes (B) n = 6. Levels of Il6 released from 3T3-L1 adipocytes after stimulation with the Nod1 ligand FK565 (10 μg/mL) for 48 h and pre-incubated for 1 h with 1 or 5 μM of the TKIs gefitinib, SB203580 or imatinib (C) n = 5. Time course of FK565-stimulated Il6 secretion in 3T3-L1 adipocytes (D) n = 5. Levels of Cxcl1 released from 3T3-L1 adipocytes after stimulation with the Tlr4 ligand LPS (0.5 μg/mL) for 48 h and pre-incubated for 1 h with 1 or 5 μM of the TKIs gefitinib, SB203580 or imatinib (E) n = 6. Time course of LPS-stimulated Cxcl1 secretion in 3T3-L1 adipocytes (F) n = 6. Levels of Il6 released from 3T3-L1 adipocytes after stimulation with the Tlr4 ligand LPS (0.5 μg/mL) for 48 h and pre-incubated for 1 h with 1 or 5 μM of the TKIs gefitinib, SB203580 or imatinib (G) n = 5. Time course of LPS-stimulated Il-6 secretion in 3T3-L1 adipocytes (H) n = 5. Values are mean ± SEM. Different letters assigned to each condition (a, b, c) denote statistical differences between groups (p < 0.05).